Usted buscó: platelet nadirs (Inglés - Maltés)

platelet studies
studji tal-plejtlets

low platelet count
għadd baxx ta' plejtlits

decreased platelet count
tnaqqis fl-għadd tal-plejtlits

median time to blood platelet and granulocyte nadirs were around 60 days after start of treatment.
il- ħin medjan sabiex il- livelli tal- plejtlits u l- granuloċiti jilħqu l - aktar livell baxx, kien ta ’ bejn wieħed u ieħor ta ’ madwar 60 jum mill- bidu tal- kura.

nadir platelet count (cells/μ l)
75, 000 – 150, 000 50, 000 – inqas minn 75, 000

in a phase i study, neutrophil and platelet count nadirs occurred at 2 to 3 weeks after intravenous administration of a single dose of xofigo.
fi studju ta’ fażi i, il-punti minimi tal-għadd tan-newtrofili u tal-plejtlits seħħew wara ġimagħtejn sa 3 ġimgħat wara għoti fil-vini ta’ doża waħda ta’ xofigo.

the mean platelet count nadir measured was approximately 40% of baseline.
il- medja ta ’ l- għadd l- iktar baxx tal- plejtlets kien bejn wieħed u ieħor 40% tal- linja bażi.

two percent of patients had a platelet count nadir < 50,000 cells/mm3.
tnejn fil-mija tal-pazjenti kellhom l- għadd ta plejtets l-aktar baxx f’livell ta’ <50,000 ċellula/mm3.

kyprolis causes thrombocytopenia through inhibition of platelet budding from megakaryocytes resulting in a classic cyclical thrombocytopenia with platelet nadirs occurring on day 8 or 15 of each 28-day cycle and usually associated with recovery to baseline by the start of the next cycle.
kyprolis jikkawża tromboċitopenija permezz tal-inibizzjoni tas-separazzjoni għat-tkabbir tal-plejtlits mill-megakaryocytes li jirriżulta fi tromboċitopenija ċiklika klassika bl-inqas għadd ta’ plejtlits li jseħħ f’jum 8 jew 15 ta’ kull ċiklu ta’ 28 jum u normalment hija assoċjata mal-irkupru mil-linja bażi sal-bidu taċ-ċiklu li jmiss.

kyprolis causes thrombocytopenia with platelet nadirs observed on day 8 or day 15 of each 28-day cycle with recovery to baseline platelet count by the start of the next cycle (see section 4.8).
kyprolis jikkawża tromboċitopenija bl-għadd l-aktar baxx ta’ plejtlits osservat f’jum 8 jew jum 15 ta’ kull ċiklu ta’ 28 jum b’irkupru tal-għadd ta’ plejtlits fil-linja bażi sal-bidu taċ-ċiklu li jmiss (ara sezzjoni 4.8).

in a population pharmacokinetics analysis of clinical trial experience there were 101 female and 169 male subjects for whom nadir neutrophil counts were available and 110 female and 174 male subjects for whom nadir platelet counts were available.
f’analiżi bil-farmakokinetiċi ta’popolazzjoni fl-esperjenza bi prova klinika kien hemm 101 mara u 169 raġel li għalihom il-valuri l-aktar baxxi tan-newtrofili kienu disponibbli u 110 mara u 174 raġel li għalihom il-valuri l-aktar baxxi tal-plejtlets kienu disponibbli.

the mean platelet count nadir measured was approximately 40% of baseline in the single-agent multiple myeloma studies and 50% in the mcl study.
il-medja tal-għadd l-iktar baxx tal-plejtlits imkejla kienet bejn wieħed u ieħor 40% tal-linja bażi fl-istudji ta’ majeloma multipla b’sustanza waħda u 50% fl- istudju ta’ mcl.

platelets
plejtlets